, Singapore
410 views

Raffles Medical Group’s H2 2021 net profit declines 7.2% to $44.88m

This is despite a 16.3% increase in its revenue during the same period.

Raffles Medical Group’s (RMG) net profit declined 7.2% to $44.88m in the second half (H2) of 2021, which ended on 31 December.

This is despite a 16.3% increase in its revenue to $379.98m in H2 2021.

Looking at full-year figures, net profit increased 29.5% to $83.72m on the back of a record revenue of $723.8m, representing a 27.4% year-on-year (YoY) increase.

Revenue growth was also recorded in all its reportable segments namely healthcare services 63.1% YoY to $458.75m, hospital services 10.6% YoY to 346.10m, and investment holdings ($39.69m).

In FY2022, the directors said it expects the medical group to remain profitable barring unforeseen circumstances, especially with its Shanghai site already operating.

“We now have hospitals in three major cities in China. With this addition to our network of medical facilities and services in the region, we can serve even more local and international patients with our Raffles brand of quality healthcare services,” Loo Choon Yong, executive chairman, Raffles Medical Group.

Join Singapore Business Review community

Follow the link s for more news on

Join Singapore Business Review community
A NOTE FROM SINGAPORE BUSINESS REVIEW

Reaching the people who run Asia's businesses is harder than it used to be.

Inboxes are crowded. Attention is short. The executives you most want to reach — the founders, CFOs, and operators who actually move budgets — are the hardest to find through the usual channels. If you're building a company, a category, or a reputation, you already know this.

We've spent twenty years building the room they read. Singapore Business Review is where senior decision makers in Singapore and across Southeast Asia come for business coverage they can't get elsewhere — in print, online, and in person at the summits and roundtables we host across seven markets.

If you have something these readers should know about — a point of view worth publishing, a product worth their attention, an event worth their time — we'd like to hear what you're trying to do.